title: EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer.
authors.forename: Hidefumi
authors.initials: H
authors.lastname: Sasaki
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Endo
authors.forename: Kotaro
authors.initials: K
authors.lastname: Mizuno
authors.forename: Motoki
authors.initials: M
authors.lastname: Yano
authors.forename: Ichiro
authors.initials: I
authors.lastname: Fukai
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Yamakawa
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Fujii
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D004273:DNA, Neoplasm / Q000235:genetics*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D000077156:Gefitinib; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D015996:Survival Rate / Q000639:trends
chemical_list: D004273:DNA, Neoplasm; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib